SEC Tracker
Get the app

Alkermes ALKS

Alkermes Q1 FY25: revenue $306.5M, down 13%; diluted EPS $0.13

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Alkermes reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$306.5M−13% from $350.4M in Q1 FY2410-Q income statement, on EDGAR
  2. Net income$22.5M−39% from $36.8M in Q1 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.13−38% from $0.21 in Q1 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$399.8M−5% from $420.8M in Q1 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$98.8M+368% from $21.1M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Alkermes files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Halozyme Therapeutics HALO public float $4.5B, Jun 30, 2025
  2. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  5. Ionis Pharmaceuticals IONS public float $5.3B, Jun 30, 2025